Movement Alert｜XtalPi Holdings Falls 5.02% in Regular Trading, Valuation Pressure Persists Despite Major Partnership and Buyback Plan

Market Focus06-11

On June 11, XtalPi Holdings declined 5.02% in regular trading, trading at 6.62 HKD/share, with trading volume of approximately 177 million HKD.

The decline comes as valuation pressure continues to weigh on shares despite a series of positive announcements. On June 9, the company disclosed a strategic AI drug discovery partnership with a leading international biopharmaceutical firm worth over 400 million USD, targeting a GPCR oral drug candidate. Simultaneously, the board approved a 100 million USD share buyback program. However, market reaction has been muted — the partnership news only triggered a brief 4% opening gap before shares reversed lower.

Although XtalPi reported revenue of 803 million RMB for fiscal year 2025, up 201.2% year-over-year, and achieved its first annual profit with adjusted net income of 258 million RMB, its dynamic price-to-earnings ratio remains elevated at approximately 212x. The broader Life Sciences Tools and Services sector also faced selling pressure, with WuXi XDC down 5.56%, Insilico Medicine down 6.28%, and WuXi Biologics down 2.22%, reflecting weak sector sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137332880?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 10:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137332880","market":"hk","top_or_hot":-1,"title":"Movement Alert｜XtalPi Holdings Falls 5.02% in Regular Trading, Valuation Pressure Persists Despite Major Partnership and Buyback Plan","media":"Market Focus","content":"<p><p>On June 11, XtalPi Holdings declined 5.02% in regular trading, trading at 6.62 HKD/share, with trading volume of approximately 177 million HKD.</p><p>The decline comes as valuation pressure continues to weigh on shares despite a series of positive announcements. On June 9, the company disclosed a strategic AI drug discovery partnership with a leading international biopharmaceutical firm worth over 400 million USD, targeting a GPCR oral drug candidate. Simultaneously, the board approved a 100 million USD share buyback program. However, market reaction has been muted — the partnership news only triggered a brief 4% opening gap before shares reversed lower.</p><p>Although XtalPi reported revenue of 803 million RMB for fiscal year 2025, up 201.2% year-over-year, and achieved its first annual profit with adjusted net income of 258 million RMB, its dynamic price-to-earnings ratio remains elevated at approximately 212x. The broader Life Sciences Tools and Services sector also faced selling pressure, with WuXi XDC down 5.56%, Insilico Medicine down 6.28%, and WuXi Biologics down 2.22%, reflecting weak sector sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜XtalPi Holdings Falls 5.02% in Regular Trading, Valuation Pressure Persists Despite Major Partnership and Buyback Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜XtalPi Holdings Falls 5.02% in Regular Trading, Valuation Pressure Persists Despite Major Partnership and Buyback Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-11 10:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 11, XtalPi Holdings declined 5.02% in regular trading, trading at 6.62 HKD/share, with trading volume of approximately 177 million HKD.</p><p>The decline comes as valuation pressure continues to weigh on shares despite a series of positive announcements. On June 9, the company disclosed a strategic AI drug discovery partnership with a leading international biopharmaceutical firm worth over 400 million USD, targeting a GPCR oral drug candidate. Simultaneously, the board approved a 100 million USD share buyback program. However, market reaction has been muted — the partnership news only triggered a brief 4% opening gap before shares reversed lower.</p><p>Although XtalPi reported revenue of 803 million RMB for fiscal year 2025, up 201.2% year-over-year, and achieved its first annual profit with adjusted net income of 258 million RMB, its dynamic price-to-earnings ratio remains elevated at approximately 212x. The broader Life Sciences Tools and Services sector also faced selling pressure, with WuXi XDC down 5.56%, Insilico Medicine down 6.28%, and WuXi Biologics down 2.22%, reflecting weak sector sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02228","symbol_name":"晶泰控股","start_time":0,"source_url":"","article_id":"1137332880","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137332880","pubTimestamp":1781145539,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 11, XtalPi Holdings declined 5.02% in regular trading, trading at 6.62 HKD/share, with trading volume of approximately 177 million HKD.The decline comes as valuation pressure continues to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02228":"晶泰控股"},"translate_title":"动向提示|XtalPi Holdings常规交易跌5.02%，尽管有重大合作伙伴关系和回购计划，估值压力依然存在","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02228":1},"content_text":"On June 11, XtalPi Holdings declined 5.02% in regular trading, trading at 6.62 HKD/share, with trading volume of approximately 177 million HKD.The decline comes as valuation pressure continues to weigh on shares despite a series of positive announcements. On June 9, the company disclosed a strategic AI drug discovery partnership with a leading international biopharmaceutical firm worth over 400 million USD, targeting a GPCR oral drug candidate. Simultaneously, the board approved a 100 million USD share buyback program. However, market reaction has been muted — the partnership news only triggered a brief 4% opening gap before shares reversed lower.Although XtalPi reported revenue of 803 million RMB for fiscal year 2025, up 201.2% year-over-year, and achieved its first annual profit with adjusted net income of 258 million RMB, its dynamic price-to-earnings ratio remains elevated at approximately 212x. The broader Life Sciences Tools and Services sector also faced selling pressure, with WuXi XDC down 5.56%, Insilico Medicine down 6.28%, and WuXi Biologics down 2.22%, reflecting weak sector sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137332880","isCrawlerRequest":true}